P=0.05), were associated with AML-unrelated death.
We presume that the lack of prognostic significance of some variables of the IPSS may be due to the effect of the cytoreductive treatment that many patients were receiving at the time of myelofibrotic transformation for the management of ET or PV.
This situation differs from that of PMF patients, in whom the risk factors at disease diagnosis are usually computed without any myelosuppressive treatment. Other factors could have also influenced on our findings. Thus, 39% of patients with constitutional symptoms received JAK inhibitors, whereas this treatment was used in only 19% of those without such symptoms at MF diagnosis. Ruxolitinib has been associated with a reduction in the risk of death compared to conventional therapy (9), which could presumably have blunted the poor prognosis associated with this feature.
In line with our results, in an Italian series (4) of 68 patients with post-PV MF, anemia was the only predictor for survival at disease presentation, whereas age and leukocyte count lacked prognostic significance. In 66 young patients with post-ET/PV MF from the Mayo Clinic (3), anemia was again an independent risk factor for shortened survival, although the strongest adverse factor was the unfavorable cytogenetics. Neither constitutional symptoms nor the leukocyte count predicted for survival.
By multivariate analysis, two variables not included in the IPSS, namely thrombocytopenia and hydroxycarbamide treatment at myelofibrotic transformation, were shown to correlate with survival. The former has been identified as a poor prognostic factor in PMF (10, 11) and post-PV MF (4). Low platelets are often associated with anemia, making it difficult to qualify thrombocytopenia as an independent prognostic factor, which was the reason why this variable was excluded from the IPSS (6). In our study, thrombocytopenia was an independent predictor for shorter survival probably because it was associated with a higher risk of AML. Such an association has also been reported in PMF (10) (11) (12) (13) . With regard to the poor prognostic significance of being on hydroxycarbamide at MF diagnosis, we think that some kind of selection bias may be operating here. Indeed, hydroxycarbamide is usually indicated in older patients and in those with more marked myeloproliferative features, what may have contributed to blur the prognostic significance of such features.
In conclusion, the results from the present study indicate that the IPSS fails to accurately discriminate different prognostic groups in post-ET/PV MF. An alternative tool is therefore required for patients' risk stratification to help physicians on therapeutic decision-making. 
